What Having a Fake Disease Taught Me About Health Care

Medical schools are training students in a form of care that the system can’t—or won’t—provide.

DOL back wage recovery hit 5-year high in 2025, despite closing fewer cases

The Wage and Hour Division released an analysis of its 2025 data, also drawing attention to an updated video series on the ...

Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew ...
TMCnet

Santhera Licenses AGAMREE® (Vamorolone) to Nxera Pharma in Japan, South Korea, Australia and New Zealand in a Deal Valued at up to USD 205 Million Plus Royalties

Exclusive licensing agreement includes USD 40 million upfront comprising USD 30 million in cash and USD 10 million equity investment at CHF 14.91 per share, a 20% premium to the 30-day VWAP. Pratteln, ...